Amber Orman1, Tulay Koru-Sengul2, Feng Miao3, Arnold Markoe1, Joseph E Panoff4. 1. Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida. 2. Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida. 3. Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida. 4. Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida. Electronic address: jpanoff@med.miami.edu.
Abstract
PURPOSE/OBJECTIVE(S): To evaluate the effects of various patient characteristics and radiation therapy treatment variables on outcomes in advanced-stage retinoblastoma. METHODS AND MATERIALS: This was a retrospective review of 41 eyes of 30 patients treated with external beam radiation therapy between June 1, 1992, and March 31, 2012, with a median follow-up time of 133 months (11 years). Outcome measures included overall survival, progression-free survival, local control, eye preservation rate, and toxicity. RESULTS: Over 90% of the eyes were stage V. Definitive external beam radiation therapy (EBRT) was delivered in 43.9% of eyes, adjuvant EBRT in 22% of eyes, and second-line/salvage EBRT in 34.1% of eyes. A relative lens sparing (RLS) technique was used in 68.3% of eyes and modified lens sparing (MLS) in 24.4% of eyes. Three eyes were treated with other techniques. Doses ≥45 Gy were used in 68.3% of eyes. Chemotherapy was a component of treatment in 53.7% of eyes. The 10-year overall survival was 87.7%, progression-free survival was 80.5%, and local control was 87.8%. White patients had significantly better overall survival than did African-American patients in univariate analysis (hazard ratio 0.09; 95% confidence interval 0.01-0.84; P=.035). Toxicity was seen in 68.3% of eyes, including 24.3% with isolated acute dermatitis. CONCLUSIONS: External beam radiation therapy continues to be an effective treatment modality for advanced retinoblastoma, achieving excellent long-term local control and survival with low rates of treatment-related toxicity and secondary malignancy.
PURPOSE/OBJECTIVE(S): To evaluate the effects of various patient characteristics and radiation therapy treatment variables on outcomes in advanced-stage retinoblastoma. METHODS AND MATERIALS: This was a retrospective review of 41 eyes of 30 patients treated with external beam radiation therapy between June 1, 1992, and March 31, 2012, with a median follow-up time of 133 months (11 years). Outcome measures included overall survival, progression-free survival, local control, eye preservation rate, and toxicity. RESULTS: Over 90% of the eyes were stage V. Definitive external beam radiation therapy (EBRT) was delivered in 43.9% of eyes, adjuvant EBRT in 22% of eyes, and second-line/salvage EBRT in 34.1% of eyes. A relative lens sparing (RLS) technique was used in 68.3% of eyes and modified lens sparing (MLS) in 24.4% of eyes. Three eyes were treated with other techniques. Doses ≥45 Gy were used in 68.3% of eyes. Chemotherapy was a component of treatment in 53.7% of eyes. The 10-year overall survival was 87.7%, progression-free survival was 80.5%, and local control was 87.8%. White patients had significantly better overall survival than did African-American patients in univariate analysis (hazard ratio 0.09; 95% confidence interval 0.01-0.84; P=.035). Toxicity was seen in 68.3% of eyes, including 24.3% with isolated acute dermatitis. CONCLUSIONS: External beam radiation therapy continues to be an effective treatment modality for advanced retinoblastoma, achieving excellent long-term local control and survival with low rates of treatment-related toxicity and secondary malignancy.
Authors: Sravani Kondapavulur; Daniel L Cooke; Andrew Kao; Matthew R Amans; Matthew Alexander; Robert Darflinger; Christopher F Dowd; Randall T Higashida; Bertil Damato; Van V Halbach; Katherine K Matthay; Steven W Hetts Journal: Interv Neuroradiol Date: 2018-01-17 Impact factor: 1.610
Authors: Kent W Mouw; Beow Y Yeap; Paul Caruso; Aaron Fay; Madhusmita Misra; Roshan V Sethi; Shannon M MacDonald; Yen-Lin Chen; Nancy J Tarbell; Torunn I Yock; Suzanne K Freitag; John E Munzenrider; Eric Grabowski; Michelle Katz; Karen Kuhlthau; Dawn DeCastro; Gena Heidary; Jessica Ciralsky; Shizuo Mukai; Helen A Shih Journal: Adv Radiat Oncol Date: 2017 Jan-Mar